medigraphic.com
ISSN 0188-2198 (Print)

2007, Number 4

<< Back Next >>

Rev Mex Cardiol 2007; 18 (4)

Obesity. A weight problem. The current and experienced therapeutic role of sibutramine. The weight of evidence

Morales VEC, González GCA, Hernández GHR

Language: Spanish
References: 76
Page: 163-172
PDF size: 141.45 Kb.


ABSTRACT

This article reviews the most recent information of therapeutic effect of Sibutramine in overweight and obesity states with and without co-morbidities. Overweight and central obesity, thought adipocyte dysfunction and lipotoxicity, are inducer of insulin resistance and the consequent Diabetes mellitus type 2 and cardiovascular disease, making desirable any strategy directed to control of corporal weight. Sibutramine is a drug which has show efficacy and safety to weight loss in 10 years mainly in clinical trials and postmarketing surveillance. Sibutramine is a neurotransmitter reuptake inhibitor of serotonin and norepinephrine in CNS, specially in hypothalamus. Paracrine increase of neurotransmitters, which are ligands of α1 and β1 adrenergic- receptors and 2A/2C serotonin receptors, causes stimulation and maintenance of satiety. In addition, Sibutramine limits down regulation of basal metabolism associated to weight loss and stimulate thermogenesis of adipocytes via activation of adipocyte β3 peripheral receptors. In long term clinical trials, has been documented mean weight loss of 10.2 kilograms in 24 months with 10 to 15 mg of Sibutramine. And also have global improve in cardiac and metabolic risk markers, specially lipidic and glycemic profile. These favorable effects are well documented of both obesity and overweight associated or not to comorbidity like Diabetes mellitus type 2, hypertension and dyslipidemia. Sibutramine is a good alternative on integral treatment of overweight and obese patients, after 10 year of marketing.


REFERENCES

  1. En Endocardiocrinología. 1ª edición. Ed. Morales-Villegas E. 2005.

  2. Morales-Villegas E. Síndrome X vs síndrome metabólico. Entendiendo sus coincidencias y sus diferencias. Arch Cardiol Mex 2006 SIV Oct-Dec: 173-188.

  3. Burley S, Dobson C, Eisenberg D, Harrison S, Kuriyan J, Petzco G. How cells obtain energy from food. pp 91-109. Chapter 2. Cell chemistry and biosynthesis. In: Molecular biology of the cell. 2nd Ed 2002. Ed. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Taylor and Francis Group.

  4. Isganaitis E, Lustig RH. Fast food, central nervous system, insulin resistance and obesity. Arterioscler Throm Vasc Biol 2005; 25: 2451-2462.

  5. Angelopoulus N, Goula A, Tolis G. Current knowledge in the neurophysiologic modulation of obesity. Metabolism Clin and Exp 2005; 54: 1202-1217.

  6. Kojima M, Hosoda H, Date Y, Nakasato M, Matzuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402(6762): 656-660.

  7. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.

  8. Shalev U, Yap J, Shaham Y. Leptin attenuates food deprivation-induced relapse to heroin seeking. J Neurosci 2001; 21: RC129: 1-5.

  9. Kawai K, Sugimoto K, Nakashima K, Miura H, Ninomiya Y. Leptin as a modulator of sweet taste sensitivities in mice. Proc Nat Acad Sci USA 2000; 97: 11044-11049.

  10. Carr KD, Tsimberg Y, Berman Y, Yamamoto N. Evidence of increased dopamine receptor signaling in food-restricted rats. Neuroscience 2003; 119: 1157-1167.

  11. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282: 1568-1575.

  12. Ahima RS, Flier JS. Leptin. Ann Rev Physiol 2000; 62: 413-437.

  13. Flier JS. Banting lecture. ADA Meeting San Diego USA 2005.

  14. Drucker DJ. Enhancing incretin action for the treatment of type-2 diabetes. Diabetes Care 2003; 26: 2929-2940.

  15. Lambeir AM, Durinx X, Scharpe S, DeMessterm I. Dipeptidyl-Peptidase-IV from bench to bedside. An update on structural properties, functions, and clinical aspects of the enzyme DPP-IV. Critical Rev in Clin Lab Sci 2003; 40: 209-294.

  16. Figlewics DP, Szot P, Chavez M, Woods SC, Veith RC. Intraventricular insulin increases dopaminergic transporter mRNA in rat VTA-substantia nigra. Brain Res 1994; 644: 331-334.

  17. Sipols AJ, Stuber GD, Klein SN, Higgins MS, Figlewics DP. Insulin and raclopride combine to decrease short-term intake of sucrose solutions. Peptide 2000; 21: 1361-1367.

  18. Figlewics DP. Adiposity signals and food reward: expanding the CNS roles of insulin and leptin. Am J Physiol Regul Integr Comp Physiol 2003; 284: R882-R892.

  19. Sipols AJ, Bayer J, Bennet R, Figlewics DP. Intraventricular insulin decreases kappa opioid-mediated sucrose intake in rats. Peptides 2002; 23: 2181-2187.

  20. Cota D, Marsicano G, Tschop M et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-431.

  21. Lusting RH, Preeyasombant C, Velazquez-Mieyer PA. Childhood obesity. In: Pescovitz OH, Eugster EA (eds). Pediatric endocrinology; mechanisms, manifestations and management. Philadelphia Lippincott Williams and Wilkins; 2003: 683-714.

  22. Lustig RH. Autonomic dysfunction of the beta-cell and the pathogenesis of obesity. Rev Endocrinol Metab Dis 2003; 4: 23-32.

  23. Prentice AM, Jebb SA. Fast foods, energy density and obesity: a possible mechanistic link. Obesity Reviews 2003; 4: 187-194.

  24. Rolls BJ, Castellanos VH, Halford JC, Kilara A, Panyam D, Pelkman CL et al. Volume of food consumed affects satiety in men. Am J Clin Nutr 1998; 67: 1170-1177.

  25. Rolls BJ, Bell EA, Castellanos VH, Chow M, Pelkman CL, Thorwart ML. Energy density but not fat content of foods affected energy intake in obese and lean women. Am J Clin Nutr 1999; 69: 863-871.

  26. Ebbeling CB, Sinclair KB, Pereira MA, Garcia-Lago E, Feldman HA, Ludwing DS. Compensation for energy intake from fase food among overweigth and lean adolescents. JAMA 2004; 291: 2828-2833.

  27. Sherwood NE, Jeffery RW, French SA, Hannan PJ, Murray DM. Predictors of weigth gain in the Pound of Prevention study. Int J Obes Relat Metab Disord 2000; 24: 395-403.

  28. Harris RB, Mitchel TD, Hebert S. Leptin-induced changes in body composition in high fad-fed mice. Exp Biol Med 2003; 228: 24-32.

  29. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1996; 45: 3-10.

  30. Stein DT, Stevenson BE, Chester MW, Basit M, Daniels MB, Turley SD et al. The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. J Clin Invest 1997; 100: 398-403.

  31. Parker DR, Weiss ST, Troisi R, Cassano PA, Vokonas PS, Landsberg L. Relationship of dietary saturated fatty acids and body habitus to serum insulin concentrations: the normative aging study. Am J Clin Nutr 1993; 58: 129-136.

  32. Mayer EJ, Newman B, Quesenberry CP, Selby JV. Usual dietary fat intake and insulin concentrations in healthy women twins. Diabetes Care 1993; 16: 1456-1469.

  33. Dobbins RL, Szczepaniak LS, Myhill J, Tamura Y, Uchino H, Giacca A et al. The composition of dietary fat directly influences glucose-stimulated insulin secretion in rats. Diabetes 2002; 51: 1825-1833.

  34. Zierath JR, Houseknecht KL, Gnudi L, Kahn BB. High fat feeding impairs insulin-stimulated GLUT-4 recruitment via an early signaling defect. Diabetes 1997; 46: 215-223.

  35. El-Haschimi K, Pierroz DD, Hileman SM, Bjorbaek C, Flier JS. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest 2000; 105: 1827-1832.

  36. Lin L, Martin R, Schaffhauser AO, York DA. Acute changes in the response to peripheral leptin with alteration in the diet composition. Am J Physiol Regil Integr Comp Physiol 2001; 280: R504-R509.

  37. Hu FB, Stamfer MJ, Manson JE, Grodstein F, Colditz GA, Speizer FE et al. Trends in the incidence of coronary heart disease and changes in diet and life style in women. N Engl J Med 2000; 343: 530-537.

  38. Ludwig DS. The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA 2002; 287: 2414-2423.

  39. Ludwig DS, Majzoub, Al-Zaharani A, Dallal GE, Blanco I, Roberts SB. High glycemic index foods, overeating, and obesity. Pediatrics 1999; 103: E261-E266.

  40. Ludwig DS. Dietary glycemic index and obesity. J Nutr 2000; 130: 280S-283S.

  41. Pereira MA, Swain J, Goldfine AB, Rifai N, Ludwig DS. Effects of a low-glycemic load diet on resting energy expenditure and heart disease risk factors during weigth loss. JAMA 2004; 292: 2482-2490.

  42. Salmeron J, Manson JE, Stampfer MJ, Colditz GA, Wing AL, Willet WC. Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA 1997; 277: 472-477.

  43. Gross LS, Li L, Ford ES, Liu S. Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. Am J Clin Nutr 2004; 79: 774-779.

  44. Anderson JW, Story LJ, Zettwoch NC, Gustafson NJ, Jefferson BS. Metabolic effects of fructose supplementation in diabetic individuals. Diabetes Care 1989; 12: 337-344.

  45. Jurgens H, Haass W, Castaneda TR, Schurmann A, Koebnick C, Dombrowski F et al. Consuming fructose sweetened beverages increases body adiposity in mice. Obes Res 2005; 13: 1146-1156.

  46. Havel PJ. Dietary fructose: implications for dysregulation of energy homeostasis and lipid-carbohydrate metabolism. Nutrition Reviews 2005; 63: 133-157.

  47. Moyer AE, Rodin J. Fructose and behavior: does fructose influence food intake and macronutrients selection? Am J Clin Nutr 1993; 58(Suppl 5): 810S-814S.

  48. Teff KL, Elliott SS, Tshop M, Kieffer TJ, Rader D, Heiman M et al. Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. J Clin Endocr Metab 2004; 89: 2963-2972.

  49. Wirfalt E, Hedblad B, Gullberg B, Mattisson I, Andren C, Rosander U et al. Food patterns and components of Metabolic Syndrome in men and women: a cross-sectional study within the Malmo Diet and Cancer cohort. Am J Epidemiol 2001; 154: 1150-1159.

  50. Pereira MA, Ludwig DS. Dietary fiber and body-weight regulation: observations and mechanisms. Pediatr Clin North Am 2001; 48: 969-980.

  51. Davies KM, Heaney RP, Recker RR, Lappe JM, Barger-Lux MJ, Rafferty K et al. Calcium intake and body weight. J Clin Endocrinol Metab 2000; 85: 4635-4638.

  52. Pereira MA, Jacobs DR, Van Horn L, Slattery ML, Kartashov AI, Ludwig DS. Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA study. JAMA 2002; 287: 2081-2089.

  53. Zemel MB, Thompson W, Milstead A, Morris K, Campbell P. Calcium and dairy acceleration of weight and fat loss during energy restriction in obese adults. Obes Res 2004; 12: 582-590.

  54. Butler SA, Slater NA, Prow MR, Aspley S, Martin KF, Heal DJ. D-Fenfluramine-induced depletion of rat brain 5-HT is prevented by fluoxetine or sibutramine pretreatment. Br J Pharmacol 1997; 120(Suppl): 350.

  55. Gundlah C, Martin KF, Heal DJ, Schjott, Auerbach SB. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J Pharmac Exp Ther 1997; 283: 581-591.

  56. Toubro S, Sorensen TI, Ronn B, Christensen NJ, Astrup A. Twenty-four-hour energy expenditure: the role of body composition, thyroid status, sympathetic activity, and family membership. J Clin Endocrinol Metab 1996; 81: 2670-2674.

  57. Walsh KM, Leen E, Lean MEJ. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int J Obes Relat Metab Disord 1999; 23: 1009-1015.

  58. Rouley HL, Butler SA, Prow MR, Dykes SG, Aspley S, Kilpatrick IC, Heal DJ. A comparison of the effects of sibutramine and other weigth-modifying drugs on extracellular dopamine in the nucleus accumbens of freely-moving rats. Synapse 2000; 38: 167-176.

  59. Kilpatrick IC, Traut M, Heal DJ. Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phenteramine and fenfluramine: a comparison with their abilities to evoke monoamine release. Int J Obes Relat Metab Disord 2001; 25: 1454-1458.

  60. Cole JO, Levin A, Beake B, Kaiser PE, Scheinbaum ML. Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines. J Clin Psycopharm 1998; 18: 231-236.

  61. Schuh LM, Schuster CR, Hopper JA, Mendel CM. Abuse liability assessment of sibutramine, a novel weight control agent. Psycho-Pharmacy 2000; 147: 339-348.

  62. Hansen DJ, Toubro S, Stock MJ, MacDonald IA, Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 1999; 23: 1016-1024.

  63. Sibutramine Clinical Summary November 2000, Abbot/Knoll data.

  64. Chapelot D, Marmonier C, Thomas T, Hanotin C. Modalities of the food intake-reducing effect of sibutramine in humans. Physiol Behav 2000; 68: 299-308.

  65. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106: 179-184.

  66. James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van Gaal LF. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 2119-2125.

  67. Smith JG, Goulder MA on behalf of the Members of the Sibutramine Clinical Study Team. Randomized-controlled trail of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001; 50: 501-512.

  68. Scholze J. Weight reduction by sibutramine in a primary care setting. Int J Obes Relat Metab Disord 2001; 25(Suppl 2): S106.

  69. Faria AN, Ribeiro-Filho FF, Lerário DDG, Kohlmann N, Ferraira SRG, Zanella MT. The effects of sibutramine in the treatment of obesity in patients with arterial hypertension. Arch Bras Cardiol 2001; 78: 172-175.

  70. Faria AN, Ribeiro-Filho FF, Kohlmann NE, Ferraira SRG, Zanella MT. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. Diabetes, Obesity and Metabolism 2005; 7: 246-253.

  71. Wirth A, Scholze J, Sharma AM, Matiba B, Boenner G. Reduced left ventricular mass after treatment of obese patients with sibutramine: and echocardiographic multicentre study. Diabetes, Obesity and Metabolism 2006; 8: 674-681.

  72. Rissanen A, Pekkarinen T, Heinanen T, Saltevo J, Taskinen MR. Weight loss profile with sibutramine in obese patients with type 2 diabetes: a double-blind, placebo-controlled study. Obes Res 1999; 7(Suppl 1): 935.

  73. McNulty S, Williams G for the International Study Group, Diabetes and Endocrinology Research Group. Sibutramine is effective for weight loss in obese, metformin-treated Type 2 diabetics. In J Obes Relat Metab Disord 2000; 24(Suppl 1): S320.

  74. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes, Obesity and Metabolism 2000; 2: 105-112.

  75. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP, and the Sibutramine/Diabetes Clinical Study Group. Diabetes, Obesity and Metabolism 2000; 2: 175-187.

  76. Astrup A, Toubro S. When, for whom and how to use sibutramine. International Journal of Obesity 2001; 25(Suppl 4): 2-7.




2020     |     www.medigraphic.com